Zenas BioPharma, Inc. (ZBIO)
29.53
+1.27
(+4.49%)
USD |
NASDAQ |
Nov 09, 14:42
Zenas BioPharma Total Assets (Quarterly) : 675.22M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 675.22M |
| June 30, 2026 | 701.69M |
| March 31, 2026 | 747.68M |
| December 31, 2025 | 383.64M |
| September 30, 2025 | 322.02M |
| June 30, 2025 | 293.08M |
| Date | Value |
|---|---|
| March 31, 2025 | 333.77M |
| December 31, 2024 | 369.97M |
| September 30, 2024 | 403.43M |
| June 30, 2024 | 199.95M |
| March 31, 2024 | 49.05M |
| December 31, 2023 | 68.18M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.794B |
| Alnylam Pharmaceuticals, Inc. | 7.995B |
| Anika Therapeutics, Inc. | 189.60M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 517.11M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 462.91M |
| Shareholders Equity (Quarterly) | 212.31M |
| Debt to Equity Ratio | 1.884 |
| Current Ratio | 9.422 |
| Net Debt Paydown Yield | -4.37% |